SunTrust Robinson Believes Amedisys (NASDAQ: AMED) Won’t Stop Here

By Carrie Williams

SunTrust Robinson analyst David S Macdonald reiterated a Buy rating on Amedisys (NASDAQ: AMED) today and set a price target of $80. The company’s shares closed yesterday at $66.32, close to its 52-week high of $66.66.

According to TipRanks.com, Macdonald is a 4-star analyst with an average return of 8.4% and a 65.1% success rate. Macdonald covers the Services sector, focusing on stocks such as American Renal Associates Holdings Inc, Encompass Health Corporation, and Walgreens Boots Alliance.

Amedisys has an analyst consensus of Strong Buy, with a price target consensus of $71.40.

Based on Amedisys’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $404 million and GAAP net loss of $3.85 million. In comparison, last year the company earned revenue of $370 million and had a net profit of $15.13 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amedisys, Inc. provides hospice and home health care services to the chronic, co-morbid and aging American population. The company focuses on delivering patient-centered care, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. It operates its business through the following business segments: Home Health and Hospice. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Amedisys was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.